Fern Anari Joins the Division of Genitourinary Medical Oncology at Fox Chase Cancer Center

In 2016, Dr. Anari joined Fox Chase Cancer Center/Temple University for a three-year fellowship in hematology/oncology. She begins full-time on August 5th.
In 2016, Dr. Anari joined Fox Chase Cancer Center/Temple University for a three-year fellowship in hematology/oncology. She begins full-time on August 5th.

PHILADELPHIA (July 23, 2019) – Fox Chase Cancer Center is pleased to announce the hiring of Fern Anari, MD, who will join the faculty as assistant professor in the Division of Genitourinary Medical Oncology within the Department of Hematology/Oncology.

Anari earned her medical degree from Rutgers Robert Wood Johnson Medical School and completed an internship and residency at Thomas Jefferson University Hospital. In 2016, she joined Fox Chase Cancer Center/Temple University for a three-year fellowship in hematology/oncology.

“We are excited to have Dr. Anari join our team and look forward to the many contributions she will bring to the department and to Fox Chase,” said Elizabeth Plimack, MD, MS, chief of the Division of Genitourinary Medical Oncology. “She is a skilled clinician and accomplished researcher, who will help us continue to provide the highest quality genitourinary oncologic care.”

Each year, Fox Chase Cancer Center welcomes six fellows who have completed an approved US residency to be part of one of the strongest combined hematology/oncology fellowship programs available. Fellows at Fox Chase train under some of the world’s most renowned and widely-published oncology experts and regularly move on to distinguished careers at academic and community medical centers around the world, including Fox Chase. Approved by the American Board of Internal Medicine and the Accreditation Council for Graduate Medical Education, the Fox Chase hematology-oncology program gives fellows exceptional flexibility to choose and pursue the career path that’s right for them.

Anari will begin at Fox Chase on August 5, 2019.

Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence six consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

For more information, call 888-369-2427

Resize Text